Minerva Therapeutics

Minerva Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. The company's lead product candidate is roluperidone, a small molecule designed to treat negative symptoms in patients with schizophrenia, which has been the subject of a New Drug Application (NDA) with the FDA. Minerva is also involved in the development of seltorexant, in collaboration with Janssen Pharmaceutica, targeting major depressive disorder and insomnia. Additionally, the company is advancing MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, for the treatment of Parkinson's disease. By targeting specific receptors such as 5-HT2A, Sigma-2, and Orexin-2, Minerva aims to address significant unmet needs in neuropsychiatric and neurological healthcare.